» Articles » PMID: 31890812

Expression Analysis Data of BCL11A and γ-globin Genes in KU812 and KG-1 cell Lines After CRISPR/Cas9-mediated BCL11A Enhancer Deletion

Overview
Journal Data Brief
Date 2020 Jan 1
PMID 31890812
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The data presented in this article are related to the research article entitled as "Targeted deletion of the BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta-thalassemia disease " [1]. BCL11A is a master regulator of γ-globin gene silencing, and suppresses fetal hemoglobin expression by association with other γ-globin suppressors, and also interacts with human beta-globin locus control region as well as intergenic region between the Aγ and δ-globin genes to reconfigure beta-globin cluster. Thus, HbF reactivation has been proposed to be an approach for the treatment of β-thalassemia through knockout of BCL11A. Accordingly, an erythroid enhancer sequence was identified that, when inactivated, led to repression of BCL11A and induction of γ-globin in the erythroid lineage [2-7]. This article describes data that obtained from BCL11A gene enhancer modification in KU812 and KG-1 cell lines using the CRISPR-Cas9 genome editing system in order to reactivate γ-globin gene expression.

Citing Articles

CRISPR-Cas Technology as a Revolutionary Genome Editing tool: Mechanisms and Biomedical Applications.

Ebrahimi S, Khosravi M, Raz A, Karimipoor M, Parvizi P Iran Biomed J. 2023; 27(5):219-46.

PMID: 37873636 PMC: 10707817. DOI: 10.61186/ibj.27.5.219.


Recent Advances in Genome-Engineering Strategies.

Boti M, Athanasopoulou K, Adamopoulos P, Sideris D, Scorilas A Genes (Basel). 2023; 14(1).

PMID: 36672870 PMC: 9859587. DOI: 10.3390/genes14010129.


Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β39-Globin Gene Editing and Induction of Fetal Hemoglobin.

Cosenza L, Zuccato C, Zurlo M, Gambari R, Finotti A Genes (Basel). 2022; 13(10).

PMID: 36292612 PMC: 9601852. DOI: 10.3390/genes13101727.


Upregulation of hsa-miR-625-5p Inhibits Invasion of Acute Myeloid Leukemia Cancer Cells through ILK/AKT Pathway.

Samieyan Dehkordi S, Mousavi S, Ebrahimi M, Alizadeh S, Hedayati Asl A, Mohammad M Cell J. 2022; 24(2):76-84.

PMID: 35279963 PMC: 8918266. DOI: 10.22074/cellj.2022.7658.


Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing.

Asmamaw M, Zawdie B Biologics. 2021; 15:353-361.

PMID: 34456559 PMC: 8388126. DOI: 10.2147/BTT.S326422.


References
1.
Cavazzana M, Antoniani C, Miccio A . Gene Therapy for β-Hemoglobinopathies. Mol Ther. 2017; 25(5):1142-1154. PMC: 5417842. DOI: 10.1016/j.ymthe.2017.03.024. View

2.
Bauer D, Orkin S . Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev. 2015; 33:62-70. PMC: 4705561. DOI: 10.1016/j.gde.2015.08.001. View

3.
Haeussler M, Schonig K, Eckert H, Eschstruth A, Mianne J, Renaud J . Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 2016; 17(1):148. PMC: 4934014. DOI: 10.1186/s13059-016-1012-2. View

4.
Rao X, Huang X, Zhou Z, Lin X . An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2015; 3(3):71-85. PMC: 4280562. View

5.
Guschin D, Waite A, Katibah G, Miller J, Holmes M, Rebar E . A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol. 2010; 649:247-56. DOI: 10.1007/978-1-60761-753-2_15. View